Skip to main content
SNYNF logo

Sanofi (SNYNF) Stock Price & Analysis

Sanofi (SNYNF) — price $96.45 (0.00%), as of the Nov 19, 2026 trading session; market cap $116B.

Educational signal · not a buy or sell recommendation · How to read this

$96.45 $0.00 (0.00%) Market Cap $116B

Sanofi · SNYNF · Healthcare · Drug Manufacturers - General

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ABBV · AbbVie Inc. · 83 /100
  • AMGN · Amgen Inc. · 84 /100
  • AZN · AstraZeneca PLC · 85 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$96.45
Change on the day0.00%
52-week range$76.76–$100.00
Market capitalisation$116B
Price / earnings (trailing)24.80
Shares traded on the day200
Beta (volatility vs the S&P 500)0.26

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $78, high $103, latest $96. $103 $78 high $103 Oct 17, 2025 Nov 19, 2026 · $96 $100Oct 17, 2025$100Oct 31, 2025$103Nov 14, 2025$100Nov 28, 2025$97Dec 12, 2025$95Dec 26, 2025$96Jan 9, 2026$93Jan 23, 2026$97Feb 6, 2026$95Feb 20, 2026$90Mar 6, 2026$89Mar 20, 2026$95Apr 2, 2026$95Apr 17, 2026$96May 1, 2026$86May 15, 2026$87May 29, 2026$89Jun 12, 2026$85Jun 26, 2026$88Jul 10, 2026$88Jul 24, 2026$88Aug 7, 2026$93Aug 21, 2026$89Sep 4, 2026$84Sep 18, 2026$78Oct 2, 2026$79Oct 16, 2026$90Oct 30, 2026$97Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Sanofi (SNYNF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Negative
Debt/Equity Moderate
ROE Neutral
Gross Margin Strong

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sanofi (SNYNF), and what does it report?

Short answer · as of

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. Healthcare / Drug Manufacturers General SEC filing business address: 46 Avenue DE LA Grande Armee, Paris, I0, 75017. It employs 76,493 people and is led by Belén Garijo López. In Q3 FY2026 it reported revenue of €15.23B and net income of €3.02B. The market values it at $116B.

2 · Latest results

What do the latest results show for Sanofi (SNYNF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of €15.23B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026€15.23B€3.02B€2.52 (diluted)
Q2 FY2026€12.30B€343M€0.29 (diluted)
Q1 FY2026€11.24B€1.61B€1.34 (diluted)
Q4 FY2025€23.73B€2.00B€1.63 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sanofi (SNYNF)?

Short answer · as of

The distress and quality screens read Altman Z 1.85 · Piotroski F 8. Trailing ratios: ROE 5.7% · ROA 5.5% · current ratio 1.12.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
9
Identified insiders
1
Purchases
9
Sales
0
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SNYNF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SNYNF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sanofi (SNYNF)?

Read these with our analysis →

SNYNF Healthcare Stock FAQ

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

How do Sanofi vaccines change its revenue profile?

Vaccines add demand tied to immunization and disease prevention alongside prescription use. Pediatric combinations, respiratory protection and travel-related vaccines allow portfolio mix to shift even when therapeutic demand is stable.

What role do Sanofi research partnerships play in its pipeline?

The partnerships extend Sanofi's reach into small molecules, antibodies, protein degradation, genome editing and artificial-intelligence-assisted discovery. They widen the opportunity set while tying some development and commercialization outcomes to counterparties.

What is the SNYNF stock price today?

The last price recorded for Sanofi (SNYNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 1 from SEC filings and earnings calls, 17 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: How do Sanofi vaccines change its revenue profile?: Business description
  • FAQ: What role do Sanofi research partnerships play in its pipeline?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.